PR
PRFX.US PRF Technologies Ltd.
- Market cap
- USD 2.31M
- P/E
- -
- P/B
- 0.15x
- ROE
- -35.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is PRFX.US undervalued?
Graham numberThe Graham number of PRF Technologies Ltd. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
PRF Technologies Ltd. fundamental analysis
No fundamental analysis for PRF Technologies Ltd. yet.
PRF Technologies Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About PRF Technologies Ltd.
PRF Technologies Ltd., a specialty pharmaceutical company, focuses on reformulation of established therapeutics in Israel. It develops OcuRing-K, a bio-erodible sustained-release implant applied to the haptic of an intraocular lens for use in cataract surgery; and PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company was formerly known as PainReform Ltd. and chang…
Full company profilePRF Technologies Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
PRF Technologies Ltd. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 0.00 | 86.0K | 0.00 | 0.00 | 17.0K | 28.0K |
| Gross Profit | - | - | -1.00K | - | -7.00K | 71.0K | -15.0K | -16.0K | -827K | -84.0K |
| Operating Income | -880K | -500K | -689K | -1.67M | -7.21M | -8.87M | -9.58M | -14.7M | -4.99M | -5.07M |
| EBITDA | -1.21M | -3.00K | -688K | -1.67M | -7.22M | -8.76M | -9.57M | -14.6M | -4.21M | -4.14M |
| Net Income | -2.09M | -828K | -1.82M | -4.05M | -7.25M | -8.79M | -9.34M | -14.6M | -4.84M | -5.59M |
| EPS | -906 | -359 | -1,173 | -2,076 | -4,432 | -4,948 | -4,282 | -804 | -7.47 | -4.50 |
| Balance Sheet | ||||||||||
| Total Assets | 214K | 81.0K | 1.16M | 17.8M | 19.1M | 12.3M | 9.93M | 4.53M | 12.0M | 19.1M |
| Total Liabilities | 3.84M | 4.54M | 6.79M | 1.18M | 991K | 1.31M | 2.69M | 2.70M | 2.71M | 2.62M |
| Shareholders' Equity | -3.63M | -4.46M | -5.62M | 16.6M | 18.1M | 11.0M | 7.24M | 1.82M | 8.54M | 15.9M |
| Cash & Short-term Investments | 187K | 40.0K | 941K | 15.7M | 16.5M | 4.10M | 8.03M | 4.26M | 4.17M | 11.5M |
| Total Debt | 3.71M | 4.52M | 6.17M | - | - | - | 86.0K | 45.0K | 21.0K | 50.0K |
| Cash Flow | ||||||||||
| Operating Cash Flow | -870K | -635K | -609K | -2.56M | -6.55M | -6.46M | -6.68M | -12.6M | -3.96M | -4.87M |
| Capital Expenditure | 10.0K | 10.0K | 10.0K | 10.0K | 50.0K | 6.00K | 9.00K | 13.0K | 2.00K | 4.00K |
| Free Cash Flow | -870K | -635K | -609K | -2.57M | -6.60M | -6.47M | -6.69M | -12.6M | -3.96M | -4.87M |
| Ratios | ||||||||||
| ROE | - | - | - | -24.4% | -40.1% | -79.8% | -129.1% | -799.8% | -56.6% | -35.2% |
| ROA | -976.6% | -1,022.2% | -156.4% | -22.8% | -38.0% | -71.3% | -94.1% | -322.4% | -40.3% | -29.3% |
| Net Profit Margin | - | - | - | - | - | -10,223.3% | - | - | -28,458.8% | -19,978.6% |
| Debt to Equity | - | - | - | - | - | - | 0.01x | 0.02x | 0.00x | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
PRF Technologies Ltd. dividends
PRF Technologies Ltd. has not paid dividends in the last 9 fiscal years.
Last stock split: 1:5 on Feb 6, 2026.
Who owns PRF Technologies Ltd.
- Insiders 5.72%
- Institutions 4.64%
- Public & others 89.64%
- Shares outstanding 3.50M
- Free float 2.87M
Top funds holding PRFX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Nasdaq Composite Index | 319.00 | 0.01% | +0.31% | Sep 2024 |
Top institutions holding PRFX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Yorkville Advisors Global, LP | 81.1K | 2.32% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 80.4K | 2.30% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 28.6K | 0.82% | +116.15% | Jun 2026 |
| UBS Group AG | 10.4K | 0.30% | +1,098.50% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 2.78K | 0.08% | +72.75% | Jun 2026 |
| Royal Bank of Canada | 233.00 | 0.01% | 0.00% | Jun 2026 |
| Advisor Group Holdings, Inc. | 40.00 | 0.00% | 0.00% | Jun 2026 |
| Rockefeller Capital Management L.P. | 1.00 | 0.00% | 0.00% | Jun 2026 |
PRF Technologies Ltd. company profile
- Company name
- PRF Technologies Ltd.
- Ticker
- PRFX.US
- ISIN
- IL0011651580
- Exchange
- USA Stocks
- Listed since
- Sep 1, 2020
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 6
- Fiscal year end
- December
- Address
- 65 Yigal Alon St., Tel Aviv, Israel, 6744316
- Phone
- 972 3 7177050
- Website
- painreform.com
About PRF Technologies Ltd.
PRF Technologies Ltd., a specialty pharmaceutical company, focuses on reformulation of established therapeutics in Israel. It develops OcuRing-K, a bio-erodible sustained-release implant applied to the haptic of an intraocular lens for use in cataract surgery; and PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company was formerly known as PainReform Ltd. and changed its name to PRF Technologies Ltd. in January 2026. PRF Technologies Ltd. was incorporated in 2007 and is based in Tel Aviv-Yafo, Israel.
PRF Technologies Ltd. management
5- Dr. Ehud Geller Ph.D.Executive Chairman
- Mr. Eyal BroderChief Financial Officer · born 1971
- Dr. Sigal Aviel eMBA, Ph.D.Chief Operating Officer · born 1964
- Mr. Efraim Cohen-AraziInterim CEO & Director · born 1955
- Ms. Rita Keynan M.Sc.Vice President of Pharmaceutical Operations · born 1969